SCS Capital Management LLC Acquires Shares of 1,711 Thermo Fisher Scientific Inc. $TMO

Key Points

• SCS Capital Management initiated a position in Thermo Fisher Scientific, purchasing 1,711 shares valued at approximately $859,000. Institutional investors and hedge funds collectively own 89.23% of the company.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $619.41. Recent quarterly results also exceeded expectations, with EPS of $6.03 and revenue of $11.99 billion.
• Company insiders sold 52,053 shares worth about $30.6 million over the past 90 days under pre-arranged trading plans, while Thermo Fisher declared a quarterly dividend of $0.47 per share.

SCS Capital Management LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,711 shares of the medical research company's stock, valued at approximately $859,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. J. Stern & Co. LLP grew its position in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. State Street Corp increased its holdings in shares of Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock valued at $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Capital World Investors lifted its position in Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Thermo Fisher Scientific by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock worth $4,728,129,000 after buying an additional 26,425 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on TMO. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 target price for the company. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. Finally, KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $619.41.

Insider Buying and Selling

In related news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company's stock, valued at $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 52,053 shares of company stock worth $30,643,589 over the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $586.62 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a market cap of $216.90 billion, a P/E ratio of 31.56, a PEG ratio of 2.39 and a beta of 0.84. The firm's 50 day moving average price is $531.72 and its 200 day moving average price is $508.48.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source